Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotypeCatherine Milch, Joseph R. Berger, Asit Parikh et al.|Journal of Neuroimmunology|2013Cited by 77
Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteersCatherine Milch, Irving H. Fox, Tim Wyant et al.|Inflammatory Bowel Diseases|2011Cited by 11
P234 Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteersCatherine Milch, Irving H. Fox, J Berger et al.|Journal of Crohn s and Colitis|2012Cited by 7